⌕

Idexx Laboratories (IDXX) vs Takeda Pharmaceutical (TAK)

Your goal
● Balanced style: every factor counts equally.
#1 FIT · LEADS
62
Takeda Pharmaceutical Co
$21.43 · $74B · as of last close
Best incomeStreet favoriteCalmest ride
of the stocks compared here

The front-runner. Leads the balanced score. Its widest win over the field is dividend & income.

#2 FIT
55
Idexx Laboratories, Inc.
$704.23 · $55B · as of last close
Highest qualityFastest grower
of the stocks compared here

The challenger. Trails the leader on the balanced score. Its widest win over the field is profitability & quality.

TAK edges ahead (62/100 vs IDXX 55) under a balanced style, mostly on dividend & income. But IDXX wins on profitability & quality, so the comparison turns on what you weight. Switch your goal above and watch the scores move.

THE SCORECARD · FACTOR BY FACTOR · the best value in each row is ticked, and a tie ticks every tied column · weight bar shows how much it counts for your goal

FactorIDXXTAK
Overall fit score
weighted for your balanced goal
55
✓ 62
Valuation
Cheaper for what you get
1×
P/E 47 · EV/EBITDA 33.7
P/E trailing
21
✓ P/E — · EV/EBITDA 25.5
fiscal 2026
44
Growth
Revenue & earnings momentum
1×
✓ —
66
—
37
Profitability & quality
Margins & return on capital
1×
✓ Net 25% · ROIC 44%
TTM through Sep 30, 2026
77
Net −3% · ROIC 0%
fiscal 2026
37
Total return
Share-price change with dividends reinvested
1×
5Y +2%/yr
54
✓ 5Y +13%/yr
76
Risk (calm = better)
Volatility & drawdown
1×
β 0.9 · DD −51%
70
✓ β 0.2 · DD −23%
99
Balance sheet†
Debt vs cash cushion
1×
✓ Net debt/EBITDA 0.4×
TTM through Sep 30, 2026
42
Net debt/EBITDA 6.9×
fiscal 2026
9
Dividend & income
Cash paid to you
1×
—
40
✓ 2.94% yield· D
97
Analyst sentiment
Forward EPS growth (consensus)
1×
Est EPS +13%/yr · 9 analysts
69
✓ Est EPS +57%/yr · 3 analysts
100
† Balance sheet is scored on 5 peer percentiles (current ratio, quick ratio, net debt/EBITDA, interest coverage and debt/equity). The cell shows one of them, so a column can lead on the printed number and still lose the row.
The letter beside the dividend yield is our dividend-safety grade (A+ to F), a read on how likely that dividend is to be cut. It does not grade the yield.
Loading chart…
WHERE EACH ONE IS STRONG
GrowthValueQualityReturnSafetyIncome
■ IDXX■ TAK
CAN YOU STOMACH THE RIDE?
Worst drawdown3-year beta vs S&P 500VolatilityHistory
IDXX−51%0.9437%5Y
TAK−23%0.1719%5Y
Drawdown and volatility are measured over five years on the same total return as the chart, dividends reinvested.
THE CASE FOR & AGAINST EACH
BULL CASE

▲ Leads on profitability & quality: Net 25% · ROIC 44% (score 77).

▲ Leads on growth: — (score 66).

BEAR CASE

▼ Weakest on dividend & income: — (score 40).

▼ Weakest on analyst sentiment: Est EPS +13%/yr · 9 analysts (score 69).

BULL CASE

▲ Leads on dividend & income: 2.94% yield (score 97).

▲ Leads on analyst sentiment: Est EPS +57%/yr · 3 analysts (score 100).

BEAR CASE

▼ Weakest on profitability & quality: Net −3% · ROIC 0% (score 37).

▼ Weakest on balance sheet (score 9). Net debt/EBITDA 6.9× is one of the 5 inputs.

WHAT COULD CHANGE THE SCORE
ValuationCurrently 21/100 (P/E 47 · EV/EBITDA 33.7). Taking it to 100 would lift the balanced score by 10 points, the biggest single move available.
Dividend & incomeCurrently 40/100 (—). Taking it to 100 would lift the balanced score by 7 points, the next biggest.
Balance sheetCurrently 9/100 (Net debt/EBITDA 6.9×). Taking it to 100 would lift the balanced score by 12 points, the biggest single move available.
GrowthCurrently 37/100 (—). Taking it to 100 would lift the balanced score by 8 points, the next biggest.
Scores are Tenet composites, 0–100, reweighted for your selected goal. Seven of the eight factors are sector percentiles; analyst sentiment is an absolute curve on forward EPS growth, capped at 100, so two very high-growth names can share the top score. Moat/durability is not scored (qualitative, not measurable). Comparison is decision-support, not a recommendation · past performance does not predict future returns · Not investment advice · prices are each company's own latest close, the newest here being Nov 13, 2026 · valuation, growth, quality and balance scores from the Nov 13, 2026 scoring run · analyst consensus, return, risk and income scores computed Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.